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Objectives: We prospectively investigated the effects of ATP-binding cassette protein-1 (ABCA1) variants
on long-term clinical outcome in patients with coronary artery disease (CAD).
Background: ABCA1 is implicated in the etiology of atherothrombosis and may offer a target to reduce
cardiovascular risk. However, the impact of ABCA1 on recurrent cardiovascular disease in a secondary
prevention setting is as of yet unknown.
Methods: We studied cause-speciﬁc 10-year mortality and quantitative coronary angiography data from
the RegressionGRowth Evaluation Statin Study (REGRESS), comprising 884male CADpatients genotyped
for promoter variants encompassing a proximal regulatory region (rs2422493, rs1800976, rs2740483
and rs1800977). Kaplan–Meier, proportional hazards and haplotype analyses were used to ascertain
single-variant and multi-marker effects on absolute risk and extent of CAD.
Results: Protection from 10-year vascular death could be attributed to the rs2422493 genotype (available
in 639 patients) T allele with absolute risk decreasing stepwise from 12.2% to 8.6% to 4.7% per each added
allele copy, HR 0.64, p=0.03 and HR 0.53, p=0.04 in the TGCC haplotype context. The TGCC (p=0.04) and
TCCT (p=0.003) haplotypes exhibited less extensive CAD.
Conclusions: On a background of contemporary secondary prevention, variation in the ABCA1 promoter
inﬂuences 10-year risk of vascular death and angiographic extent of CAD in men. These insights con-
tribute to identiﬁcation of patients sharing a speciﬁc prognosis, understanding of its etiological basis and
s of ridevelopment of strategie
. IntroductionEffective risk reduction in coronary artery disease (CAD)
atients requires among others statin and anti-platelet therapy.
Abbreviations: CAD, coronary artery disease; ABCA1, ATP-binding cassette pro-
ein A1; REGRESS, Regression Growth Evaluation Statin Study; QCA, quantitative
oronary angiography; MSD, mean segment diameter; MOD, minimal obstruction
iameter; LD, linkage disequilibrium; ZNF202, zinc ﬁnger 202; HR, hazard ratio;
DL, high-density lipoprotein.
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Currently however, an unmet medical need exists for additional
pharmacological targets of secondary prevention.
Several lines of evidence suggest that the transmembrane ATP-
binding Cassette protein A1 (ABCA1) may be a promising target
in this context. Recent epidemiological studies in have implicated
ABCA1 in cardiovascular risk in the general population [1,2], an
effect that currently seems independent of HDL cholesterol [3].
Experimental over-expression of human ABCA1 in mice results in
protection from aortic atherosclerosis [4], while ABCA1-deﬁcient
mice exhibit mild hemorrhagic diathesis [5]. ABCA1 deﬁciency in
patients results in familial analphalipoproteinemia (Tangier Dis-
ease), a rare and monogenic disorder [6] presenting with diffuse
cellular cholesterol ester depositions and thrombocyte dysfunc-
Open access under the Elsevier OA license.tion [7–9]. At the molecular level, ABCA1 is known to facilitate
lipid translocation which is determined by transcriptional activity
of the ABCA1 gene and thereby under control of several responsive
elements identiﬁed at its locus [10–14]. The body of evidence con-
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Fig. 1. Genomic organization of regulatory sites, common variants and absolute risk at the proximal ABCA1 promoter. The four bi-allelic variants in the current analysis
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oncompass a region comprising regulatory sites such as those for the ZNF202, LXR/
he distance relative to translation starting point is displayed along its chromosom
nd absolute risk of ten-year morality endpoints in the REGRESS sample stratiﬁed f
erning regulation of ABCA1 transcription has been predominantly
ocused on the promoter region with a number of common gene
olymorphisms situated in close proximity to currently known
BCA1 regulatory sites (see Fig. 1) [9]. These polymorphisms may
hus modulate transcription. In fact, a recent functionality-study
eported that carriers of the T allele of the dbSNP rs2422493 poly-
orphism (C/T, formerly reported as −477), exhibit in vitro lower
BCA1mRNA levels in explanted carotid arterialmacrophages [15].
Thus, ABCA1 constitutes a potential target to further reduce
therothrombotic risk in a secondary prevention setting. However
ts engagement in long-term clinical prognosis in CAD patients
emains undeﬁned. Prospective investigation of key regulatory
ites at the ABCA1 locus is one approach to conﬁrm and quan-
ify its prognostic contribution in a contemporary secondary
revention setting. We therefore prospectively evaluated the
mpact of genetic variation in the ABCA1 promoter region on 10-
ear mortality outcomes and baseline angiographical outcomes
n an established secondary prevention cohort of patients with
AD.
. Methods
.1. Subjects with coronary artery disease
The study participants were derived from the Regression
rowth Evaluation Statin Study (REGRESS) study which enrolled
84 males, non-diabetic patients with symptomatic coronary
rtery disease between 1989 and 1993. The trial design and main
ndings have been reported previously [16,17]. In brief, the pri-
ary objectives of this angiographic trial were to evaluate effects
f 24 months of 40mg pravastatin therapy on the evolution of
therosclerotic lesions in male patients with documented coro-
ary artery disease. Within the framework of the trial, clinical
nd angiographic follow-up was documented after the initial 2-
ear trial. A distinct protective effect of pravastatin treatment was
bserved in the 24 month REGRESS trial and concurrent statin tri-nd myeloid zinc ﬁnger (MZF1) factors displayed (see Refs. [11,13,14], respectively).
ition on the long arm of chromosome 9. On the right hand side, frequency of alleles
otype is displayed.
als, prompting the study coordinators to urge all participants and
treatingphysicians to start (placebogroup)or continue (pravastatin
group) statin therapy also according to national and international
guidelines. A survey in the REGRESS cohort conducted 5 years after
completion of the trial showed that 91% of patients were using
statin therapy and were therefore on a background of contempo-
rary secondary prevention. All participants gave written informed
consent and the clinical trial and subsequent DNA-studies were
approved by all seven institutional review boards of the par-
ticipating centers and by the medical ethics committees of all
centers.
2.2. Mortality 10-year follow-up
In addition to the 2-year follow-up from the original trial, 10-
year follow-up data of the participantswere obtained by extracting
cause-speciﬁc mortality from nation-wide registries. All diagnoses
in these registers are coded according to the International Classi-
ﬁcation of Diseases (ICD9 and ICD10). The research protocol was
approved by the institutional review board and ethics commit-
tee of the coordinating center (University Medical Center Utrecht).
The study database, comprising all 884 REGRESS participants, was
linked to the registers on the basis of birth date, sex and postal
address code [18].As is customarydue toprivacy legislation,patient
names were omitted in the linkage process. On a per-patient basis,
historical registers of the Dutch inhabitants were searched for this
unique combination of characteristics, and once found, this auto-
matically merged migration history over the follow-up time. The
vital status of the participants was then obtained through linking
municipal administration registries using a 6-charactered postal
code. Out of the 884 participants, 861 (97%) could be uniquely
traced with the above method. The 23 patients who could not be
uniquely traced were right-censored at the end of the 24-month
follow-up.
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Table 1
Study participants’ characteristics at baseline according to rs 2422493 genotype of ABCA1.
CC
n=177
CT
n=351
TT
n=111
p-Value
Demographic
Age in years (SD) 57.0 (8.2) 55.3 (8.1) 56.4 (8.0) 0.07*
Body mass index (kg/m2) (SD) 26.0 (2.9) 26.1 (2.5) 26.2 (3.1) 0.88*
Systolic RR (mmHg) (SD) 134.8 (18.2) 134.6 (17.7) 137.0 (19.5) 0.46*
Diastolic RR (mmHg) (SD) 81.2 (10.8) 81.3 (9.9) 82.0 (9.9) 0.77*
Current smoking 24% 28% 29% 0.62†
History of hypertension 26% 29% 35% 0.25†
Familial heart disease 53% 48% 47% 0.50†
Previous MI (%) 48% 49% 49% 0.96†
Angiographical
Mean baseline MOD (mm), median (min–max) 1.71 (0.8–2.7) 1.76 (0.8–3.1) 1.74 (0.6–3.1) 0.08*
Mean delta MOD (mm), median (min–max) −0.07 (−1.8;
−0.5)
−0.06 (−4.0;
−0.4)
−0.04 (−0.9;
−0.3)
0.90*
Mean delta MSD, mm (SD) −0.06 (0.22) −0.09 (0.19) −0.10 (0.20) 0.33*
Baseline MSD (mm) (SD) 2.67 (0.36) 2.75 (0.40) 2.72 (0.37 0.17*
No of vessels diseased 1 35% 44% 41% 0.31†
2 38% 33% 35%
3 27% 22% 24%
Biochemical
Fasting glucose (mmol/l) 5.2 (1.2) 5.4 (1.2) 5.3 (1.2) 0.21*
Total cholesterol (mmol/l 5.89 (0.92) 6.05 (0.86) 6.0 (0.88) 0.13*
HDL-C (mmol/l) 0.91 (0.23) 0.92 (0.21) 0.93 (0.23) 0.82*
LDL-C (mmol/l) 4.19 (0.82) 4.31 (0.80) 4.25 (0.80) 0.25*
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a* One-way ANOVA.
† Pearsons’ Chi-square test.
.3. Outcome events
In the outcome events analyses, we considered the primary
auses of death. The composite endpoint “deathdue to vascular dis-
ase” consisted of all primary causes of deathwithin the ICD9 codes
10–414 (Ischemic Heart Disease), 430–438 (Cerebrovascular dis-
ase), 440–448 (Diseases of arteries, arterioles and capillaries)
nd ICD10 codes I20–I25 (Ischemic Heart Disease), I60–I69 (Cere-
rovascular disease), I70–I79 (Diseases of arteries, arterioles and
apillaries) and F01 (Vascular dementia).
.4. DNA analyses and selection of variants in regulatory regions
A previous analysis in REGRESS, examined the effects of ten
enetic variants situated in ABCA1 regulatory regions comprising
he proximal promoter, intron 1 and exons 1 and 2 untranslated
egions [9]. The pattern of linkage disequilibrium among these ten
reviously described variants is depicted in online supplemental
ig. 1A, deﬁning a region with minimal evidence of historical
ecombination situated in theproximalpromoter. Furthermore, the
ody of evidence regarding functionality has been predominantly
ocusedon thepromoter region. For these reasons, the current long-
erm analysis concentrated on the four variants and reconstructed
aplotypes encompassing the proximal promoter region. These
ariants comprised rs2422493 (previously reported as C-477T or
-565T), rs1800976 (previously reported as G-191C), rs2740483
previously reportedasC-17G) and rs1800977 (previously reported
s T69C). Notably, these variants are also located in close proximity
f known regulatory sites in the promoter (see Fig. 1). Genotypes of
he REGRESS participants for whomDNAwas available were ascer-
ained by restriction fragment length polymorphism assays using
ligonucleotides and endonucleases as described previously [9,19].
.5. Lipoprotein cholesterol content measurementsTotal cholesterol was measured with an enzymatic kit
Boehringer Mannheim) and calibrated with a human serum
alibrator. HDL cholesterol was measured after precipitation of
polipoprotein B-containing lipoproteins with a 4% tungstatesolution and centrifugation, and the triglycerides were analyzed
enzymatically (Bayer/Technicon) by a technique that included free
glycerol [16]. LDL cholesterol was calculated according to the
Friedewald formula (LDL-Cholesterol = (Total Cholesterol)− (HDL-
Cholesterol)−0.45×Triglycerides).
2.6. Angiographic outcomes
Patients underwent coronary arteriography upon enrollment,
according to a uniform previously described [16] protocol. After
completion of the trial, angiograms were analyzed by quantita-
tive coronary angiography (QCA): the average per patient mean
segment diameter (MSD), reﬂecting the extent of diffuse obstruc-
tive coronary artery disease, and per patient average minimal
obstruction diameter (MOD), reﬂecting extent of focal obstructive
coronary artery disease were ascertained as described previously
[16]. The current analysis included QCA parameters from baseline
angiograms, which were available from 99.4% of the study popu-
lation [16]. Furthermore, the change (delta) reﬂecting progression
of atherosclerosis over the two-year follow-up time, constituting
a primary angiographic endpoint of the randomized clinical trial,
could be ascertained in 73.8% of the cohort [16] and was also
included as an endpoint of the current genetic study.
2.7. Data analyses
Theabsolute risk ofmortality outcomes amonggenotypegroups
was explored and temporal patterns of risk were visualized by
means of the Kaplan–Meier method.
The effects of gene variants on outcomes were estimated using
regression analyses. To explore solistic effects of gene variants on
time-to-event, univariate proportional hazards (Cox’ regression)
modelswereﬁtted andHazardRatios (HR) calculatedusing SPSS for
Windows, release 14.0 (SPSS Inc, Chicago, IL, USA). Given the strong
linkagedisequilibriumbetween thevariants studied, no formal cor-
rection for multiple testing was performed. Interaction between
smoking and rs2422493 genotype (as previously suggested [15])
was explored by multivariable Cox’ models including smoking,
genotype and the interaction term. In order to providemore insight
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Fig. 2. Temporal patterns of 10-year risk by rs2422493 of ABCA1. Survival curves60 J.J. Regieli et al. / Athero
n relationships found, the role of possible intermediate factorswas
lso explored in multivariate analyses. First, this included an anal-
sis adjusting for HDL-C, LDL-C, triglycerides, hypertension and
andomization group. Second, this included an analysis adjusting
or baseline MOD.
The mode of inheritance exerting the effects of ABCA1 gene
ariants remains unknown. Therefore, we compared recessive,
ominant and additive models, and selected the optimal model to
escribe the data based on the lowest Akaike Information Criterion.
he additivemodel appeared tomeet these criteria for allmortality
utcomes.
To explore the combined effects of multiple linked variants
n the ABCA1 promoter region, a haplotype-based approach was
ndertaken. The haplo.stats package in R for Windows version
.9.0 (http://www.r-project.org) was used to estimate prevalence
f haplotypes within the unphased genotype dataset and the
aplo.glm function was used for estimating haplotype-effects
n baseline coronary arterial diameters (MOD and MSD). For
aplotype-effects on time-to-event, the survival analysis function
f the application Thesias [20,21], release 3.1 was used. For all hap-
otype analyses, additive inheritance effects were assumed. The
inkage disequilibrium structure between variants was calculated
nd visualised using the application Haploview [22], release 4.0.
Demographic, clinical and angiographic characteristics and con-
entrations of lipids between the three genotypes of rs2422493
ere tabulated in Table 1.
Throughout, a two-tailed p-value of 0.05 was interpreted as
ndicating a statistically signiﬁcant difference. Analyses were per-
ormed by two of the authors (J.J.R. and A.H.Z.) and all authors had
ull access to the data and take responsibility for its integrity. All
uthors have read and agree to the manuscript as written.
. Results
.1. Distribution of allele frequencies
Genotype data for the four studied ABCA1 promoter variants,
omprising the numbers of available genotypes and allele fre-
uency distributions are displayed in Fig. 1. For the rs2422493
ariant, Table 1 displays baseline characteristics stratiﬁed by geno-
ype, which was available from 639 participants due to DNA stock
imitations. No signiﬁcant differences were observed between the
enotypes in baseline CAD risk factors including lipoprotein proﬁle,
ngiographic or lifestyle parameters.
.2. ABCA1 variation, cardiovascular risk and angiographic
xtent of CAD
For all four polymorphisms, absolute risk of vascular mortality
nd all cause mortality in genotype groups are listed in Fig. 1. After
0 years of follow-up, carriers of theminor rs2422493 (T) allele had
considerably lower risk of fatal vascular complications, as com-
ared to major (C) allele carriers. A marked allele-dose effect was
isible from the survival curves displayed in Fig. 2. For instance, the
0-year absolute risk of death due to vascular diseasewas as low as
.7% (standard error 2.1%) inhomozygoteminor allele (TT) patients,
hereas it appeared8.6% (standard error 1.6%) inheterozygote (CT)
atients and reached 12.2% (standard error 2.6%) in homozygote
ajor allele (CC) patients as displayed also in Fig. 1. As displayed
n Table 2, the T allele thus marks a state of protection from death
ue to vascular disease,HR0.64 (95% conﬁdence interval 0.42–0.97,
=0.03). This effect remained robust upon adjustment for random-
zation group, HR 0.63 (95% conﬁdence interval 0.42–0.97, p=0.03).
This effect also remained robust upon adjustment for random-
zation group, hypertension, LDL and HDL (HR 0.61 (0.40–0.95),by genotype are displayed for all-cause mortality (upper panel) and mortality from
vascular disease (lower panel). Follow-up time in years is displayed horizontally.
p=0.03), but lost statistical signiﬁcance upon correction for base-
line MOD (HR 0.68 (0.45–1.1, p=0.08)).
All-cause mortality effect did not reach signiﬁcance, unad-
justed HR 0.76 (95% conﬁdence interval 0.57–1.01, p=0.06) nor
adjusted for randomization group (HR 0.76 (95% conﬁdence inter-
val 0.57–1.01, p=0.06). Further, no signiﬁcant effects in univariate
analyses were observed for the other three genetic variants (data
not displayed). An interaction analysis revealed signiﬁcant ampli-
ﬁcation of the rs2422493 genotype effect by smoking status at
baseline (see Table 2). Notably, among smokers the T allele marked
a higher risk of mortality from all-causes (HR 0.45 (95% conﬁdence
interval 0.26–0.78), p=0.004) and from vascular disease (HR 0.28
(95% conﬁdence interval 0.12–0.70), p=0.006), whereas this effect
was absent in thenon-smoking strata of both endpoints (p for inter-
action=0.04 for vascular mortality and p for interaction=0.02 for
all-cause mortality). There was no interaction between rs2422493
and BMI on both endpoints (data not shown).
Five haplotypes meeting the prevalence estimation threshold
of 5% were derived, entered in subsequent haplotype-effects anal-
ysis, and displayed in themiddle of Fig. 3. The effects of the separate
haplotypes on coronary arterial diameters at baseline andmortality
outcomes are presented in Fig. 3, left and right sides respectively.
Haplotype effects analysis identiﬁed that the TGCC haplotype was
signiﬁcantly associated with wider mean coronary arterial diam-
eters (MSD) at baseline of the study (regression coefﬁcient 0.092,
standard error 0.04, p=0.04), and a protective state from vascu-
lar disease mortality at 10 years of follow-up (HR 0.53 (95% CI
0.28–0.98),p=0.04).Moreover theTCCThaplotypehada signiﬁcant
effect (regression coefﬁcient 0.113, standard error 0.04, p=0.003)
on focal coronary stenosis (MOD) at baseline of the study, but no
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Table 2
Effect of rs2422493 genotype of ABCA1 on 10-year survival outcomes. Absolute risk (and SE) are displayed per genotype on the left. Hazard ratios (HR, with corresponding
95% conﬁdence interval), p-value per each additional T allele copy are displayed on the right for the overall group and stratiﬁed for current smoking.
Ten-year outcome rs2422493 genotype
Absolute risk (standard error) Overall Smokers Non-smokers
CC (n=177) CT (n=351) TT (n=111) Per-allele HR
(95% CI)
p-Value
Per-allele HR
(95% CI)
p-Value
Per-allele HR
(95% CI)
p-Value
Vascular mortality 1%
(2.6%)
8.6%
(1.6%)
4.7%
(2.1%)
0.64
(0.42–0.97)
p=0.03
0.28
(0.12–0.69)
p=0.006
0.84
(0.52–1.36)
p=0.47
%
%)
e
d
p
g
(
4
t
e
a
s
F
r
d
gAll-cause mortality 21.5%
(3.2%)
18.8%
(2.3%)
13.2
(3.7
ffect of this haplotype was observed on mortality outcomes. No
etectable effects of haplotypes on 2-year progression of CADwere
resent, and univariate analyses revealed no signiﬁcant effects of
enotypes on extent or two-year progression of atherosclerosis
data not displayed).
. Discussion
In an effort to deﬁne new targets of secondary prevention,
o date, the genetic determinants of recurrent athero-thrombotic
vents inpatientswith establishedCADrepresent anunderexposed
spect of cardiovascular genetics. The present ﬁndings in such a
econdary prevention setting show the signiﬁcance of common
ig. 3. Haplotype effects on angiographic and ten-year survival outcomes. On the left side
eﬂecting extent of focal disease and mean MSD, inversely reﬂecting extent of diffuse dis
erived from the REGRESS sample. On the right hand side, survival effects are displayed
eneral linear model assessment of effect relative to the most common haplotype serving0.76
(0.57–1.01)
p=0.06
0.45
(0.26–0.78)
p=0.004
0.94
(0.67–1.32)
p=0.71
genetic variation at key regulatory sites in the ABCA1 promoter.
Effects of ABCA promoter variation on absolute risk of 10-year vas-
cular mortality and angiographic outcomes were observed in 639
men from the REGRESS cohort with known baseline CAD.
First, we found that carriership of the T allele at rs2422493
markedly reduced the absolute risk of vascular mortality in a dose-
dependent manner, with an estimated 12.2% 10-year risk in non
carriers versus 4.5% in carriers of two T alleles (per-copy HR 0.64,
95% CI 0.42–0.97, p=0.03). Second, a multi-marker analysis, which
integrates variation in this regulatory region, identiﬁed that one
arrangement of linked alleles (the TGCC haplotype, with estimated
prevalence of 16.3% in the REGRESS sample) confers signiﬁcantly
lesser extent of diffuse coronary stenosis (MSD) on QCA at study
, quantitative coronary angiographic phenotype estimations (meanMOD, inversely
ease, both in mm) are displayed for the ﬁve common (prevalence >5%) haplotypes
in terms of hazard ratio (HR) with 95% conﬁdence intervals. p-values pertain to
as reference in all haplotype analyses.
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aseline, and this haplotype accordingly also confers a lower rela-
ive risk of 10-year vascular mortality (HR 0.53, 95% CI 0.28–0.98,
= 0.04). Furthermore the TCCT haplotype (prevalence 10.2%) was
dentiﬁed to confer a lesser extent of focal coronary stenosis (MOD).
f note, both these haplotypes comprise the T allele at rs2422493
nd the angiographic ﬁndings correspondwith the current 10-year
ortality effect of that single variant.
.1. Context of the present ﬁndings
Noteworthy, thus far there is lack of genome-wide studies to
ocument riskof recurrent events in a secondaryprevention setting
f patients with CAD. A prospective candidate gene-based study of
ADpatients from the LCAS cohort could not detect the effects from
he present report [19], albeit in a smaller cohort (n=368) and over
shorter follow up time (2.5 years). Likewise, case–control data
uggested no single-variant or haplotype effect in the ECTIM study
f 800 myocardial infarction cases and 776 healthy controls [20].
evertheless, in synergy with the current ﬁndings, a nested case
ontrol study in women from the Nurses Health Studies, described
protective effect (OR 0.6 [0.4–0.9]) of the T allele of rs2422493
bserving 243 cases of coronary heart disease and 484 healthy con-
rols [23]. Next, a study of 6-year clinical outcomes in 120 young
ale survivorsof amyocardial infarction showedaprotectiveeffect
f the T allele of rs2422493 on a composite cardiovascular endpoint
24]. Therefore, the current ﬁndings on this variant are compat-
ble with and extend available prognostic evidence with 10-year
ortality data.
A previous analysis in REGRESS [9] had shown signiﬁcant effects
f rs1800976 and rs1800977 on the composite occurrence of death,
yocardial infarction, stroke, transient ischemic attacks and coro-
ary revascularization procedures after 2 years of follow-up. In the
urrent 10-year mortality outcomes, these effects were not found.
ome explanations may include the fact that the endpoints were
ifferent, the duration of follow-upwas longer and the use of statin
herapy was present in the vast majority of patients over the last 8
ears of the follow-up period.
Regarding extent of vascular disease, to the best of our knowl-
dge, no previous data on ABCA1 haplotype-effects have been
eported. Data on a single-variant effect of rs2422493 have been
eported in the LCAS trial cohort, which described that the number
f qualifying lesions (30–75% stenosis) was signiﬁcantly higher in
resence of the T allele among the 340 participants [19]. However,
allele carriers in that study exhibited no trend towards higher
xtent of CAD in terms of other indices such as the QCA derived
inimal luminal diameter, and this agreeswith the present results.
ext, similar to the REGRESS ﬁndings, no effect of rs2422493 on
umber of vessels diseased was observed among 1166 patients
ith angiographically documented CAD [15]. However, a sub-
roup analysis from that study suggested that among the 296
on-smokers in that study, the T allelewas dose-dependently asso-
iated with a higher number of diseased vessels. This prompted us
o investigate whether the current 10-year follow-up data show
n interactionwith smoking in REGRESS. Intriguingly, we observed
n inverse interaction with an augmented protective effect of the
allele among smokers (see Table 2). As an explanation for these
pposing ﬁndings and interactions on different endpoints it might
e hypothesized that thrombotic processes such as platelet acti-
ation, which has been suggested to depend on ABCA1 function
8], exert divergent effects on respectively angiographic extent of
therosclerosis and eventually development of fatal vascular com-
lications. This could be true in particular in presence of smoking,
known trigger for platelet activation.
Furthermore, the current mortality effects of rs242249 without
orresponding differences in HDL over genotype groups (Table 1)is 218 (2011) 457–463
as is consistent with other reports [15,19], might indicate that the
impact could be tissue speciﬁc.
4.2. Potential mechanism
The exact mechanism underlying the effects of ABCA1 promoter
variation in cardiovascular disease cannot be brought forward from
the current data. In several ways, a possible explanation involves
ZNF202, which has a binding site within the studied region and
is regarded a prominent down-regulator of ABCA1 transcription
[11,25,26]. In this context, there are limited functional data on the
effects of rs2422493 which suggest that carriership of the C allele
confers stronger nuclear protein binding in vitro [15]. It is therefore
tempting to speculate that C allele carriers in vivo exhibited higher
ZNF202binding afﬁnity, thusmore suppression ofABCA1 transcrip-
tion and subsequently impaired reverse cholesterol transport with
hazardous prognostic effects in vivo.
On the other hand, however, the C allele of rs2422493 was
associated with higher ABCA1 mRNA expression in vitro [15], and
at present consistently exhibits hazardous prognostic effects in
patients. Furthermore, prospective ﬁndings in the Copenhagen City
Heart Study suggested an excess cardiovascular risk in presence
of variants determining lower ZNF202 expression [27], which is
known to parallel high ABCA1 expression [28]. Onemight therefore
question the conventional role attributed to ABCA1 in cardiovas-
cular risk and alternatively reconsider in vivo functions of ABCA1
such as its suspected role in platelet activation [8], which clearly
justiﬁes further investigation. Of note, an involvement of ABCA1 in
thrombotic processesmight provide additional insight in the lesser
than expected cardiovascular risk in Tangier disease patients [29]
despite lacking HDL.
4.3. Study strengths and limitations
To appreciate these ﬁndings, some aspects of our study merit
consideration. First, the data originate from a randomized trial in
which assessment of the beneﬁts of pravastatin treatmentwere the
primary objective. Because the study medication taken during two
years of the follow-up time, was allocated at random, i.e., irrespec-
tiveof genotype, thiswill nothaveaffectedourﬁndings. Second, our
follow-up data set was not complete for all patients: 3% of the full
cohort could not be uniquely identiﬁed in the mortality registries.
Since these patientswere right-censored at lost-to-follow-up time,
again it seems unlikely that this would have affected the primary
outcome of the current study. We elected to calculate actuarial
survival across genotypes, in contrast to the case–control design.
Survival analysis enabled us to efﬁciently study all available infor-
mation, including that of censoredparticipants. Third, an important
issue is that the results in this study were obtained in a cohort of
male Caucasian patients with established CAD. Conﬁrmation of the
present result in other trials including female patients and patients
of different ethnicity is needed. Nevertheless, these are the ﬁrst
prospective data which describe the long-term effects of ABCA1
promoter variants on fatal vascular complications in a contempo-
rary secondary prevention setting, and strongly afﬁrm a role of
these variants in determining cardiovascular risk.
5. Conclusion
On a background of contemporary secondary prevention, vari-
ation in the ABCA1 promoter determines 10-year risk of vascular
death and angiographic extent of CAD inmen. The current prospec-
tive genetic data conﬁrm and quantify the prognostic contribution
of ABCA1 in recurrent cardiovascular events andwill help to strate-
gize additional forms of risk reduction in CAD.
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